tereotactic radiosurgery (SRS) is widely used as a treatment option for brain arteriovenous malformations (AVMs), particularly for small-to moderate-sized nidi located in deep or eloquent brain areas associated with an elevated surgical risk. 10, 11, 16, 25, 49, 60 Cyst formation after SRS for AVM is an uncommon, delayed complication, which can become symptomatic and necessitate surgical intervention. 34, 42, 54, 55, 63, 64 The current literature on post-SRS cyst formation in AVM patients is limited by a paucity of studies reporting the incidence of cyst formation, the prolonged temporal relationship between SRS and cyst formation, and the clinical manifestations and management of post-SRS cysts. 4,7, 8,14,22,27,28, 32, 35-37, 41, 42, 54, 63, 64,69 Additionally, there is considerable variation in the data regarding cyst formation because of differences in baseline patient and AVM characteristics, SRS modalities and treatment strategies, follow-up durations, and reporting of radiological and clinical end points. 4, 30, 35, 44, 54 Overlap of study cohorts further confounds our ability to ascertain meaningful relationships between preoperative ABBREVIATIONS AVM = arteriovenous malformation; GKRS = Gamma Knife radiosurgery; LINAC = linear accelerator; RIC = radiation-induced change; SRS = stereotactic radiosurgery. OBJECTIVE Cyst formation can occasionally occur after stereotactic radiosurgery (SRS) for brain arteriovenous malformations (AVMs). Given the limited data regarding post-SRS cyst formation in patients with AVM, the time course, natural history, and management of this delayed complication are poorly defined. The aim of this systematic review was to determine the incidence, time course, and optimal management of cyst formation after SRS for AVMs. METHODS A literature review was performed using PubMed to identify studies reporting cyst formation in AVM patients treated with SRS. Baseline and outcomes data, including the incidence and management of post-SRS cysts, were extracted from each study that reported follow-up duration. The mean time to cyst formation was calculated from the subset of studies that reported individual patient data. RESULTS Based on pooled data from 22 studies comprising the incidence analysis, the overall rate of post-SRS cyst formation was 3.0% (78/2619 patients). Among the 26 post-SRS cyst patients with available AVM obliteration data, nidal obliteration was achieved in 20 (76.9%). Of the 64 cyst patients with available symptomatology and management data, 21 (32.8%) were symptomatic; 21 cysts (32.8%) were treated with surgical intervention, whereas the remaining 43 (67.2%) were managed conservatively. Based on a subset of 19 studies reporting individual time-to-cyst-formation data from 63 patients, the mean latency period to post-SRS cyst formation was 78 months (6.5 years). CONCLUSIONS Cyst formation is an uncommon complication after SRS for AVMs, with a relatively long latency period. The majority of post-SRS cysts are asymptomatic and can be managed conservatively, although enlarging or symptomatic cysts may require surgical intervention. Long-term follow-up of AVM patients is crucial to the appropriate diagnosis and management of post-SRS cysts.
factors and post-SRS cyst formation. 26, 34, 54 Therefore, the aims of this systematic review were to 1) quantify the incidence of cyst formation after SRS for AVM, 2) determine the latency period between AVM SRS and cyst formation, and 3) evaluate the management options for post-SRS cysts in AVM patients.
Methods

Literature Search and Inclusion Criteria
This review follows the guidelines set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. A literature review was performed using PubMed on September 1, 2016, with the following search phrase: "arteriovenous malformations AND radiosurgery AND cyst." The studies were screened by title and abstract to ascertain fulfillment of inclusion criteria, which were as follows: 1) number of AVM patients who developed a cyst after SRS was reported; 2) each patient with a post-SRS cyst was represented only once among all of the studies included for analysis; 3) size of the overall cohort of AVM patients treated with SRS was reported; 4) patients were treated with SRS using the Gamma Knife (GKRS), linear accelerator (LINAC), or proton beam systems, in a single session or a dose-or volume-staged approach; 5) follow-up duration after SRS was reported; and 6) study was written in English. To meet the aforementioned inclusion criteria, only the most recent study with the greatest number of patients diagnosed with post-SRS cysts was used from a set of overlapping studies.
Data Extraction
Patient demographics, AVM characteristics, SRS treatment parameters, and outcome and complication data were extracted from each of the eligible studies. Demographic data included the number of AVM patients treated with SRS, sex, age, and follow-up duration. Arteriovenous malformation characteristics included nidus volume, prior AVM hemorrhage, and prior nidal embolization. Stereotactic radiosurgery treatment parameters included margin dose, maximum dose, and isodose line. Outcome and complication data included AVM obliteration, time to obliteration, post-SRS cyst formation, latency period between SRS and cyst formation, symptomatic radiationinduced changes (RICs), post-SRS hemorrhage, and death. Radiation-induced changes were defined as perinidal T2-weighted hyperintensities on follow-up MRI, and only clinically symptomatic RICs were recorded from each study. For those patients who developed post-SRS cysts, data regarding the time interval between SRS and cyst formation, association with complete nidal obliteration, presence or absence of symptoms associated with the cyst, and management of the cyst were recorded, when available. We defined post-SRS cyst formation as the de novo development of a fluid-filled, proteinaceous, and/or hemorrhagic sac within or adjacent to the site of the original AVM nidus.
Statistical Analysis
All statistical analyses were performed using MATLAB (version R2016a, MathWorks). For studies included in the analysis of cyst incidence, descriptive statistics were calculated for baseline and post-SRS outcomes data. Post-SRS cyst data were pooled from all eligible studies for the calculation of cyst incidence. The incidence of cyst formation was calculated by dividing the total number of AVM patients who developed a cyst after SRS by the total number of AVM patients treated with SRS. For the studies with individual patient data regarding the time interval between SRS and cyst formation, the mean latency period to cyst formation was calculated.
Results
Study Selection
The literature search yielded a total of 59 studies, from which 52 were selected based on title and abstract; 20 studies were then eliminated based on a failure to meet the inclusion criteria, yielding 32 studies eligible for at least one analysis. Of the 32 eligible studies, 22 studies reported sufficient data to allow inclusion in the analysis for post-SRS cyst incidence, and 19 studies reported sufficient data to allow inclusion in the analysis for latency period to cyst formation ( Fig. 1) . Table 1 summarizes the patient, AVM, and treatment characteristics of the 22 studies, comprising a total of 2619 AVM patients treated with SRS, which were included in the cyst incidence analysis. The frequency of the female sex was 46.8% (962/2053 patients). The median age ranged from 12 to 46 years. The median AVM volume ranged from 1.4 to 48.8 cm 3 . Prior AVM hemorrhage had occurred in 41.8% of patients (920/2200), and the proportion of ruptured AVMs ranged from 0% to 83.3%, among the studies. Prior embolization had been performed in 21.6% of patients (462/2135 patients), and the proportion of embolized AVMs ranged from 0% to 100.0%.
Overall Demographic and Treatment Characteristics
Gamma Knife radiosurgery was exclusively used in 20 studies (90.9%), and LINAC was exclusively used in 2 studies (9.1%). Volume-staged SRS was used in 1 study, dose-staged or hypofractionated SRS was used in 1 study, and repeat SRS was used in 2 studies. The median margin and maximum doses ranged from 16 to 24 Gy and 28 to 44 Gy, respectively. The median isodose line ranged from 50% to 80%. The median follow-up duration of all SRStreated AVM patients in each cohort ranged from 31 to 199 months (2.6-16.6 years).
Cyst Formation Incidence, Latency, and Management
The data regarding post-SRS cyst formation are summarized in Table 2 . The mean incidence of cyst formation for all studies was 4.4% (95% CI 2.0%-6.8%). Cyst formation rates were 4.1% (95% CI 1.5%-6.7%) in the 20 studies using GKRS, compared with 6.9% (95% CI 6.4%-7.4%) in the 2 studies using LINAC. Based on pooled data, the incidence of post-SRS cyst formation was 3.0% (78/2619 patients) for all studies. The pooled rates of cyst formation were 2.9% (74/2562 patients) in the studies using GKRS and 7.0% (4/57 patients) in the studies using LINAC. Of the 26 post-SRS cysts for which AVM oblit-eration data were available, 76.9% (20/26) Table 3 summarizes the time-to-cyst-formation data from the 19 studies that reported individual patient data, comprising a total of 63 patients with post-SRS cysts. The mean latency period between SRS and cyst formation was 78 months (6.5 years), and individual latency periods ranged from 6 to 240 months (0.5-12.0 years). Figure 2 is a histogram of the incidence of cyst formation in these 63 patients.
Obliteration and Complication Rates
The posttreatment data from the 21 studies included in the cyst incidence analysis are summarized in Table  2 . The mean complete AVM obliteration rate was 65.4% (95% CI 56.3%-74.6%). Based on pooled data, obliteration was achieved in 65.5% (1450/2215 patients). The median time to obliteration ranged from 2.5 to 8.3 years. The mean rates of symptomatic RIC, post-SRS hemorrhage, and mortality were 8.5% (95% CI 4.9%-12.0%), 13.2% (95% CI 3.3%-23.2%), and 6.9% (95% CI 4.1%-9.8%), respectively. Based on pooled data, the rates of symptomatic RIC, post-SRS hemorrhage, and mortality were 8.6% (165/1907 patients), 8.8% (191/2162 patients), and 6.0% (92/1542 patients), respectively.
Discussion
Cyst formation following SRS treatment of AVM is one of the least common complications. 18, 24, 54, 61 Because of its relative rarity and the prolonged follow-up duration necessary to detect its occurrence, the pathobiology, clinical implications, and overall impact of delayed cyst formation on the risk-to-benefit profile of SRS for AVM remain incompletely defined. 50, 58 Given our synthesis of the available literature, we estimate that approximately 3% of AVM patients will develop a cyst after SRS. However, since 70% of post-SRS cysts were asymptomatic, the rate of symptomatic cyst formation after SRS for an AVM may only be 1%. 
Factors Associated With Post-SRS Cyst Formation
We found a mean latency period of 6.5 years between SRS and cyst formation. In general, cyst formation occurs later than more common post-SRS complications, such as RICs and post-SRS hemorrhage. 19, 20, 21, 23, 29, 53, 67 Therefore, studies with longer follow-up periods tended to report a higher incidence of cyst formation, which emphasizes the importance of long-term surveillance after SRS for AVM. Specifically, patients who develop new neurological symptoms after AVM obliteration should undergo neuroimaging to screen for cyst formation. Pan et al. reported an overall post-SRS cyst incidence of 1.6%, which increased to 3.6% if only those patients with at least 5 years of follow-up were considered. 54 This suggests that the rate of cyst detection may positively correlate with follow-up duration.
Several demographic factors, AVM angioarchitectural features, treatment parameters, and post-SRS outcomes have been associated with cyst formation. 26, 34, 54 Ding et al. reported a cyst incidence of 2.3% at a mean follow-up of 7.9 years in a cohort of 444 unruptured AVMs; in their analysis, radiological evidence of RIC was significantly associated with cyst formation. 22 Izawa et al. reported a cyst incidence of 3.4% at a mean follow-up of 6.8 years; their analysis found higher SRS maximal dose, larger nidus volume, lobar AVM location, and obliteration to be predictors of cyst formation. 34 In our analysis, we found that the majority of post-SRS cysts (77%) occurred in patients with obliterated nidi, which suggests that follow-up of AVM patients treated with SRS should not be abandoned after obliteration is achieved. Pan et al. found RIC and prior nidal embolization to be significantly associated with cyst formation, while the relationship between prior AVM hemorrhage and cyst formation approached Mean latency of cyst formation: 78.2 mos (6.5 yrs).
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statistical significance. 54 These findings suggest that the pathophysiology of delayed cyst formation is distinct from that of post-SRS hemorrhage. 2, 15, 34, 65, 66 Indeed, histopathological examination of resected cysts suggests that cyst formation occurs secondary to a chronic, organized response to radiation-induced vascular telangiectasia and wall damage, which promotes microhemorrhage and protein exudation. 59 It is possible that prior AVM hemorrhage and embolization increase tissue susceptibility to damage, thereby increasing the risk of cyst formation. 6, 52 The risk of cyst formation was found to be higher for AVM patients treated with LINAC than in those treated with GKRS (7% vs 3%, respectively, in the pooled analysis). Because of the insufficient statistical power of the available literature, additional data are necessary to perform a more rigorous evaluation of the relationship between the SRS treatment modality and cyst formation. Differences in dosimetry not only in the immediate planned target volume but also at the lower isodose lines such as the 12-Gy isodose volume should be examined as potential contributing factors for discrepancies in cyst formation between SRS delivery platforms.
Kihlström et al. reported the highest rate of cyst formation (28%) among the studies included in our analysis, a rate that was more than 3 times higher than the second highest rate of cyst incidence (7.4%) documented by Maruyama et al. 42, 47 We offer the following observations to put these findings into perspective. First, the Kihlström study had a particularly lengthy mean follow-up duration of 14 years. Second, only patients who attained complete AVM obliteration were included in that study, and cyst formation may correlate with nidal occlusion. 34 Third, their study reported the highest proportion of ruptured AVMs treated with SRS (83.3%) among the included studies. Since prior AVM hemorrhage may be correlated with cyst formation, the high rate of prior hemorrhage could also partially account for the elevated post-SRS cyst incidence. 54 However, all 5 cysts in the study were between 1 and 2 cm in diameter, asymptomatic, and managed conservatively.
Management of Post-SRS Cysts
The optimal management of post-SRS cysts is not well defined. In general, asymptomatic cysts should be managed conservatively, and some cysts have been shown to spontaneously regress over time. However, enlarging cysts may require treatment, even in the absence of symptoms, particularly if the cyst is located in the vicinity of deep or eloquent brain area. 28, 47, 59, 62 Significant mass effect secondary to the cyst, intracystic loculations and septations, and residual AVM nidus adjacent to the cyst are all factors that may favor craniotomy for cyst resection. 33, 55 Simple cyst anatomy, significant medical comorbidities, or refusal of craniotomy may favor cystoperitoneal shunt or Ommaya reservoir placement. Stereotactic drainage alone may be less effective than shunting since cysts have the potential to recur. 51, 55 Currently, no medical therapy is known to be effective for post-SRS cysts given our incomplete understanding of cyst pathogenesis. Shuto et al. analyzed the histopathology of 28 post-SRS cysts and identified angiogenic and inflammatory components. 59 These authors postulated that post-SRS cysts were on the opposite end of the same pathobiological spectrum as chronic encapsulating hematomas. Future studies may seek to investigate the effect of antiangiogenic (for example, bevacizumab) or antiinflammatory (for example, dexamethasone) medications on cyst size and morphology. 12 In the context of the aforementioned surgical and medical therapeutic uncertainty regarding optimal cyst management, we recommend surgical intervention for an enlarging cyst with a volume > 8 cm 3 and for any cyst causing newfound neurological signs or symptoms. Specifically, we typically recommend shunt placement or aspiration for deep-seated cysts and resection for superficially located ones. Small, asymptomatic cysts can generally be observed with serial neuroimaging studies and correlated with the patient's neurological examination.
Study Limitations
Heterogeneity of the baseline and outcomes data among the studies limits our ability to draw definitive conclusions regarding the incidence of cyst formation after SRS for AVM. Variability in follow-up durations after SRS may affect our estimates of cyst incidence. Specifically, the inclusion of studies with a median follow-up of less than 5 years may have resulted in an underestimation of cyst incidence, whereas reporting bias of cyst complications may have resulted in an overestimation. Additionally, given the paucity of data regarding post-SRS cysts, we included studies that used a variety of both primary SRS treatment paradigms and salvage therapies. 3, 49 Several of the studies included in this review identified various risk factors for cyst formation (for example, RIC, SRS dose, AVM volume and location, obliteration rate, and prior nidal embolization). Unfortunately, given the lack of individual patient data, especially for patients who did not develop post-SRS cysts, we were unable to perform analyses of the pooled data to identify predictors of cyst formation. Specifically, we were unable to ascertain the effect of nidal morphology, SRS dose planning, number and timing of SRS treatments, and time interval between prior AVM interventions and SRS on cyst formation. Additionally, the lack of sufficient granularity with respect to individual patient data prevented us from performing a time-dependent analysis (for example, Kaplan-Meier method) for cyst formation. We were unable to ascertain the specific clinical manifestations of symptomatic cysts (for example, seizure, focal neurological deficit, headache). 9, 13, 14, 17, 57 The safety, efficacy, and durability of the various surgical options for cysts requiring intervention could not be determined. All studies were retrospective in design, and unclear risks of bias were assumed for retrospective studies.
Conclusions
The incidence of cyst formation after SRS for AVM is 3%, with a latency period of approximately 7 years. Therefore, long-term follow-up is paramount for AVM patients treated with SRS because of the substantial delay between treatment and cyst development. The majority of post-SRS cysts are asymptomatic and require only observation. Surgical intervention should be considered for symptomatic or enlarging cysts, with options including craniotomy for resection, cystoperitoneal shunt placement, stereotactic drainage, and Ommaya reservoir implantation.
